Plain-English translation of NCT07647744 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing , a new type of immunotherapy for people with advanced kidney cancer that has already been treated with other drugs. The treatment works by using your own immune cells that have been modified in a lab to recognize and attack cancer cells. Researchers are carefully studying how safe this medication is and what dose works best.
Kidney cancer that has spread to other parts of the body is very difficult to treat, especially after patients have already tried other immunotherapy options. This trial exists to see if the new treatment can help people whose cancer has not responded well to standard therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive a single infusion of the modified immune cells through an IV. Before treatment, a small number of your own blood cells will be collected through a process called apheresis (similar to donating plasma), then sent to a lab where they are modified to recognize cancer cells. The trial uses a careful step-by-step approach, starting with lower doses in small groups of patients and watching closely for any side effects before moving to higher doses. You will have multiple follow-up appointments to monitor your health and how your cancer responds to the treatment.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China